Skip to content
Screener

Twist Bioscience Corporation TWST NGS applications — Revenue

Other product segments

DNA synthesis and protein solutions
$53.27M+27.9%

Similar metrics at other companies

Oracle logo
ORCLCloud Applications — Revenue
$4.13B+10.2%
Tempus AI, Inc. logo
TEMAI Applications — Revenue
$5.03M+63.4%
Modine Manufacturing logo
MODOn Highway Applications — Revenue
$179.1M-0.6%
Tempus AI, Inc. logo
TEMData And Applications — Revenue
$93.15M—
SolarEdge Technologies logo
SEDGBatteries For Pv Applications — Revenue
$125.99M+86.3%
Fluence Energy, Inc. logo
FLNCDigital Applications And Solutions — Revenue
$2.45M+37.0%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$6.84B+338%
Enterprise value$6.83B+370%
P/S16.7×+12.4×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0001581280-26-000040
(in thousands)Three months ended March 31, 2026Three months ended March 31, 2025Six months ended March 31, 2026Six months ended March 31, 2025
DNA synthesis and protein solutions$53,27441,647$104,33481,718
NGS applications57,44151,146110,07999,788
Total$110,715$92,793$214,413$181,506

Item 1. Financial Statements (unaudited)

FAQ

What is Twist Bioscience Corporation's NGS applications — revenue?
Twist Bioscience Corporation (TWST) reported NGS applications — revenue of $57.44M in Q1 2026.
How has Twist Bioscience Corporation's NGS applications — revenue changed year-over-year?
Twist Bioscience Corporation's NGS applications — revenue increased by 12.3% year-over-year, from $51.15M to $57.44M.
What is the long-term trend for Twist Bioscience Corporation's NGS applications — revenue?
Over 4 years (2021 to 2025), Twist Bioscience Corporation's NGS applications — revenue has grown at a 30.1% compound annual growth rate (CAGR), from $72.67M to $208.1M.
What does NGS applications — revenue mean?
This metric represents the total revenue generated from the sale of products and services specifically designed for Next-Generation Sequencing (NGS) workflows. It captures the financial performance of tools used in library preparation and target enrichment, reflecting the company's market penetration in genomics and precision medicine. Growth in this segment indicates successful adoption of the company's synthetic DNA platform within the broader sequencing ecosystem.

Ask your AI about Twist Bioscience Corporation's ngs applications — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude